Category: Mergers and Acquisitions

February 6, 2023

Thermo Fisher Scientific recently announced that it had become a founding sponsor of Momentum Labs, a collaborative laboratory and office space to be located in Alachua, Fla. The venture, spearheaded by Gainesville real estate development firm Concept Companies, is designed […]

February 3, 2023

Aardex Group – a company focused on remote research and healthcare adherence – and Cambridge Cognition have firmed a partnership up to provide monitoring during hybrid and decentralised clinical trials (DCTs). The link-up will involve the incorporation of Aardex’s MEMS […]

February 1, 2023

Andelyn Biosciences, a gene therapy contract development and manufacturing organization (CDMO), has partnered with Odylia Therapeutics, a nonprofit 501(c)(3) biotech focused on accelerating rare disease drug development, to manufacture a novel gene therapy (OT-004) to treat vision loss caused by […]

January 26, 2023

Roche’s alliance with France’s Sysnav Healthcare is in the area of movement disorders, and will build on the tech company’s wearable magneto-inertial sensor device for 3D movement tracking, which has already been accepted as a digital endpoint for use in […]

January 25, 2023

Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, has entered a collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company. The collaboration will enable Stevanato […]

January 24, 2023

The partnership between Sanofi and CytoReason – for an undisclosed, multimillion dollar amount – forms part of an ongoing collaboration begun in 2021, which originally focused on obtaining advanced mechanistic insights for asthma endotypes. The collaboration takes CytoReason’s partnering with […]

January 23, 2023

Syner-G BioPharma Group, a provider of pharmaceutical science and regulatory consulting services, has acquired RMC Pharmaceutical Solutions (RMC). RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas. Financial terms were not disclosed. […]

January 20, 2023

Charles River Laboratories International Inc. and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s viral vector […]

January 19, 2023

Sun Pharmaceutical Industries and Concert Pharmaceuticals, Inc. entered a definitive agreement under which Sun Pharma will acquire Concert through an upfront payment of $576 million. Concert stockholders will also receive up to an additional $3.50 per share of common stock […]

January 19, 2023

CEPI is a partnership between public, private, philanthropic, and civil organisations to develop vaccines against future epidemics and pandemics. The agreement, worth $4.3 million, is the first to be announced as part of CEPI’s call in January 2022 for proposals […]

January 18, 2023

AbbVie and US-based Anima Biotech (Anima) have formed a collaboration to discover and develop messenger RNA (mRNA) biology modulators for three targets across oncology and immunology. In the collaboration, Anima will use its mRNA Lightning technology platform to discover novel […]

January 18, 2023

The takeover comes a few months after Bayer stepped up the digital capabilities of its radiology business with the launch of AI-powered software for X-ray, MRI, and CT imaging under the Calantic Digital Solutions umbrella brand. The launch of Calantic […]

January 17, 2023

Antibodies targeting the protein Claudin18.2, as Flame’s FL-301 does, have been the focus of some biotechnology dealmaking over the past year, involving companies like Turning Point Therapeutics, Elevation Oncology and even AstraZeneca. Claudin18.2 is expressed in gastrointestinal and pancreatic cancers, […]

January 17, 2023

Shares in the company fell sharply this morning after the announcement of the deal, which will see the two companies combine behind lead programme ELI-002, an immunotherapy targeting KRAS-driven cancers that is currently in a phase 1 trial in pancreatic […]

January 13, 2023

Alora Pharmaceuticals announced that its wholly owned subsidiary, Sovereign Pharmaceuticals, has acquired, through bankruptcy proceedings, substantially all of Monarch PCM’s manufacturing capabilities located in Fort Worth, TX. The acquisition, which closed on January 4, 2022, included all of Monarch’s equipment […]

January 11, 2023

The partners will use Anima’s mRNA Lightning platform to discover novel mRNA biology modulators for the collaboration targets, with AbbVie gaining exclusive rights to licence, further develop and commercialise the resulting programmes. In exchange, an upfront payment of $42m will […]

January 10, 2023

The deal, billed as BioNTech’s largest to date and unveiled at the JP Morgan healthcare conference today, includes $362 million upfront with another £200 million on offer if performance targets are met. The two companies have already been working together […]

January 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]

January 9, 2023

The agreement values Boston-based Albireo at $952 million, with shareholders in the company also in line for another $10-per-share payout in a contingent value right (CVR) if Bylvay (odevixibat) gets approved for a follow-up indication. Albireo secured approval in the […]

January 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease […]